Mode
Text Size
Log in / Sign up
N/A N=62 Randomized Triple-blind Prevention

Phlebotomy to Prevent Blood Loss in Major Hepatic Resections

Liver Neoplasms · Hepatectomy

Enrolled (actual)
62
Serious AEs
1.6%
Results posted
Mar 2021
Primary outcome: Primary: Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels — 862; 872; 761; 872 mL

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Phlebotomy (Procedure); Citrated whole blood collection bag (Device)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Ottawa Hospital Research Institute
Primary completion
Mar 2018

Outcome Measures

OutcomeResultp-value
PRIMARY
Total Intraoperative Blood Loss, by Measurement of Change in Hemoglobin Levels
862; 872; 761; 872; 1116; 1249
PRIMARY
Trial Feasibility
62
SECONDARY
Blood Product Transfusion Rates
1; 1; 5; 3; 5; 4
SECONDARY
Perioperative Morbidity (Dindo-Clavien Grade 3b of Higher) and Mortality
10; 15; 2; 3
SECONDARY
Changes in Physiologic Parameters (CVP)
8; 7; 8; 7.5
SECONDARY
Change in Physiologic Parameters (Cardiac Index)
3.5; 4.2; 3.5; 3.9

Summary

Major liver resection is associated with substantial intraoperative blood loss. Blood loss in elective liver surgery is a significant factor of perioperative morbidity and mortality, as well as possibly long-term oncologic outcome. The purpose of this study is to use whole blood phlebotomy to decrease the central venous pressure, resulting in a state of relative hypovolemia. It is hypothesized that this intervention will lead to a decrease in blood loss at the time of liver resection.

Eligibility Criteria

Inclusion Criteria

  • Any patient being considered for a major elective liver resection will be considered for trial enrollment. Patients who are undergoing a concurrent additional abdominal or thoracic procedure (eg. colonic resection) will also be included.

Exclusion Criteria

  • Age 1.5 not on warfarin and/or platelets count 35 umol/L)
  • Presence of active infection
  • Preoperative autologous blood donation
  • Hemoglobin <100 g/L
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02548910). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search